Some additional info was provided as follows:
This amended Form 4 is filed to correct (a) the exercise price, which was inadvertently reported as $3.30, (b) the transaction date, which was inadvertently reported as August 11, 2014 and (c) the expiration date, which was inadvertently reported as August 11, 2024.
This amended Form 4 is filed to correct the exerc
isable date. The options vest monthly over 48 months, commencing on September 12, 2014, which was inadvertently reported as September 11, 2014.
Each restricted stock unit (RSU) represents a contingent right to receive one share of the issuer's common stock at settlement.
This amended Form 4 is filed to correct the exercisable date. Twenty-five percent of the total shares underlying the RSU vest annually on the later of (i) each anniversary of August 12, 2014, which was inadvertently reported as August 11, 2014; and (ii) the first day thereafter during which the issuer's trading window is open.
The RSUs expire 30 days from the date they vest.
The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here.
To receive a free e-mail notification whenever OncoGenex Pharmaceuticals Inc. makes a similar move, sign up!
Other recent filings from the company include the following:
Great Point Partners just provided an update on its share ownership of OncoGenex Pharmaceuticals Inc. - Feb. 17, 2015
OncoGenex Pharmaceuticals: Entry Into A Material Definitive Agreement - Feb. 12, 2015